NCT07609901 — Radboud University Medical Center cancer vaccine trial
Preventive Dendritic Cell Vaccination for Lynch Syndrome Carriers
Registry record
| Registry ID | NCT07609901 ↗ |
|---|---|
| Lead sponsor | Radboud University Medical Center |
| Collaborators | Dutch National Health Care Institute |
| Phase | Phase 3 |
| Status | Not Yet Recruiting |
| Indication | Lynch Syndrome |
| Enrollment | 372 participants (target) |
| Start date | 2026-10-01 |
| Primary completion | 2032-10-01 (est.) |
| Last registry update | 27 May 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07609901), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07609901?
NCT07609901 (Preventive Dendritic Cell Vaccination for Lynch Syndrome Carriers) is registered on ClinicalTrials.gov as Phase 3, sponsored by Radboud University Medical Center.
Is NCT07609901 recruiting?
As of the 2026-05-27 registry update, NCT07609901 is listed as "Not Yet Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07609901?
The lead sponsor is Radboud University Medical Center. Collaborators: Dutch National Health Care Institute.
What condition does NCT07609901 study?
The registered condition is Lynch Syndrome. Primary completion is listed as 2032-10-01 (estimated).
Are results available for NCT07609901?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07609901.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.